Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus (as Mounjaro) and, more recently, for chronic weight management in adults with obesity or overweight with weight-related comorbidities (as Zepbound)
The peptides in this category signal the body to repair mitochondria, switch fuel sources, activate fat-burning pathways, and produce energy more reliably without stimulants that wear off or crash
(PubMed) Weir DG, Scott JM
Purity, potency, and contamination vary wildly
GHK-Cu, the parent compound of AHK-Cu, can be alternated in cycles to compare acetylated versus non-acetylated effects on follicle response
Contact us today to schedule your consultation and learn how B12/MIC injections can be integrated into your personalized health plan